Core Viewpoint - A-Mark Precious Metals (AMRK) has seen a 7.6% increase in share price over the past four weeks, closing at $25.01, with analysts suggesting a potential upside of 61.9% based on a mean price target of $40.5 [1][11]. Price Targets - The average price target for AMRK ranges from a low of $29.00 to a high of $63.00, with a standard deviation of $15.8, indicating variability among analysts [2][9]. - The lowest estimate suggests a 16% increase from the current price, while the highest estimate indicates a potential upside of 151.9% [2]. Analyst Sentiment - Analysts have shown increasing optimism regarding AMRK's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [4][11]. - Over the past 30 days, one estimate has increased, leading to a 26.1% rise in the Zacks Consensus Estimate for the current year [12]. Zacks Rank - AMRK holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of AMRK's potential gains, it does provide a directional guide for price movement [14].

Group 1 - Enliven Therapeutics, Inc. (ELVN) shares have increased by 0.8% over the past four weeks, closing at $19.92, with a mean price target of $41.13 indicating a potential upside of 106.5% [1] - The average of eight short-term price targets ranges from a low of $33.00 to a high of $52.00, with a standard deviation of $6.66, suggesting a potential increase of 65.7% to 161% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, with two estimates moving up in the last 30 days and the Zacks Consensus Estimate increasing by 8.8% [11][12] Group 2 - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - The consensus price target, while not entirely reliable, suggests a positive direction for price movement, which could guide further research into the stock's fundamentals [14]

Group 1: Stock Performance and Price Targets - Exodus Movement, Inc. (EXOD) closed at $27.49, with a 0.6% gain over the past four weeks, and a mean price target of $56.86 indicating a 106.8% upside potential [1] - The average price target ranges from a low of $45.00 to a high of $70.00, with a standard deviation of $8.99, suggesting a potential increase of 63.7% to 154.6% from the current price [2] - Analysts show strong agreement on the company's ability to report better earnings, which supports the view of potential upside [4] Group 2: Analyst Insights and Earnings Estimates - Analysts' growing optimism regarding EXOD's earnings prospects is reflected in the upward revisions of EPS estimates, which correlate with near-term stock price movements [9] - Over the last 30 days, two estimates have increased, leading to a Zacks Consensus Estimate increase of 158% [10] - EXOD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Group 3: Price Target Reliability - While consensus price targets are popular among investors, their reliability as indicators of stock price direction is often questioned [3][5] - Analysts may set overly optimistic price targets due to business incentives, which can lead to inflated estimates [6] - A low standard deviation in price targets indicates a high degree of agreement among analysts, serving as a starting point for further research [7]

Core Viewpoint - Omnicell (OMCL) shows potential for significant upside, with a mean price target of $44.4 indicating a 39.4% increase from the current price of $31.86 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $9.13, indicating variability among analysts [2] - The lowest estimate is $34.00, suggesting a 6.7% increase, while the highest estimate is $55.00, indicating a potential surge of 72.6% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about Omnicell's earnings prospects, with a strong consensus in revising EPS estimates higher [11] - The Zacks Consensus Estimate for the current year has risen by 24.6% over the past month, with no negative revisions [12] - OMCL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While consensus price targets are often sought after, they may not reliably indicate actual stock price movements [3][7] - Analysts may set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Core Viewpoint - Elastic (ESTC) shares have increased by 6.2% recently, with a mean price target of $119.83 suggesting a potential upside of 40.8% from the current price of $85.09 [1] Price Targets and Analyst Estimates - The mean estimate consists of 24 short-term price targets with a standard deviation of $13.6, indicating variability among analysts [2] - The lowest estimate is $87.00, suggesting a 2.2% increase, while the highest estimate is $150.00, indicating a potential surge of 76.3% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [7] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has risen by 1.6% over the past month, with two estimates increasing and no negative revisions [10] - ESTC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - While price targets are often sought after, they can mislead investors and should not be the sole basis for investment decisions [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

Group 1: Stock Performance and Price Targets - Shares of Build-A-Bear (BBW) have increased by 15.9% over the past four weeks, closing at $59.63, with a mean price target of $80 indicating a potential upside of 34.2% [1] - The average price target ranges from a low of $75.00 to a high of $85.00, with a standard deviation of $5, suggesting a potential increase of 25.8% to 42.6% from the current price level [2] Group 2: Analyst Sentiment and Earnings Estimates - Analysts show strong agreement on BBW's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, three earnings estimates for BBW have been revised higher, leading to a 5% increase in the Zacks Consensus Estimate [10] - BBW holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Group 3: Price Target Reliability - While price targets are commonly referenced by investors, they can often mislead, as empirical research indicates that they rarely predict actual stock price movements [5][6] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research [7]

Group 1 - CorMedix (CRMD) shares have increased by 21.4% over the past four weeks, closing at $14.64, with a mean price target of $19.33 indicating a potential upside of 32% [1] - The average price targets from analysts range from a low of $17.00 to a high of $21.00, with a standard deviation of $1.37, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about CRMD's earnings prospects, as indicated by a 53.6% increase in the Zacks Consensus Estimate for the current year over the past month [10][11] Group 2 - The Zacks Rank for CRMD is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, supporting the expectation of an upside in CRMD [9]

Core Viewpoint - OppFi Inc. (OPFI) shows potential for significant upside, with a mean price target of $14 indicating a 36.1% increase from the current price of $10.29 [1] Price Target Analysis - The average price target consists of three estimates ranging from $12.50 to $16.00, with a standard deviation of $1.8, suggesting a variability in analyst predictions [2] - The lowest estimate indicates a 21.5% increase, while the highest suggests a 55.5% upside [2] - A low standard deviation indicates a strong agreement among analysts regarding the price movement direction [7] Earnings Estimates - Analysts are optimistic about OPFI's earnings prospects, with a consensus indicating higher earnings estimates compared to previous predictions [4][9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 15.5%, with two estimates moving higher and no negative revisions [10] Zacks Rank - OPFI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of OPFI's potential gains, it does provide a useful guide for the direction of price movement [12]

Group 1 - Solaris Resources Inc. (SLSR) shares have increased by 7.7% over the past four weeks, closing at $5.34, with a mean price target of $10.73 indicating a potential upside of 100.9% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $2.13, where the lowest estimate of $8.76 suggests a 64% increase, and the highest estimate of $13.05 indicates a 144.4% surge [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 34.3% increase in the Zacks Consensus Estimate for the current year [9][10] Group 2 - The Zacks Rank for SLSR is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [11] - While price targets can provide insights, they should be approached with skepticism, as they may not reliably indicate actual stock price movements [8][12] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [6]

Core Viewpoint - Edgewise Therapeutics, Inc. (EWTX) shows significant upside potential with a mean price target of $39.17, indicating a 173% increase from its last trading price of $14.35 [1][11]. Price Targets and Analyst Consensus - The average price target for EWTX is based on 12 short-term estimates, ranging from a low of $14.00 to a high of $51.00, with a standard deviation of $12.96, suggesting variability in analyst predictions [2][9]. - The lowest estimate indicates a potential decline of 2.4%, while the highest suggests a 255.4% upside [2]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about EWTX's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - The Zacks Consensus Estimate for the current year has risen by 9.1% over the past month, with eight estimates increasing and no negative revisions [12]. - EWTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research indicates that they rarely predict actual stock price movements accurately [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].